Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04750707
Other study ID # REC REF 2019-147
Secondary ID R01HD096559
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date March 9, 2021
Est. completion date June 30, 2024

Study information

Verified date August 2023
Source Global Health Uganda LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually. Affected children suffer chronic ill health with some having frequent hospitalization. The patients are also at a high risk of brain injury arising from small and large cerebral blood vessel damage in SCA, also called sickle cell vasculopathy (SCV). SCV is associated with the high risk of stroke. Such injury may manifest with neurological and cognitive impairment. An abnormal blood flow to the brain, as measured by a Doppler Ultrasound scan is a known risk factor for stroke. The hypothesis is that hydroxyurea therapy will prevent, stabilize or improve SCV and its effects. The study is an open label, single arm clinical trial to test the impact of hydroxyurea treatment in 270 children with SCA starting at ages 3-9 years. Following baseline assessments, all participants will begin hydroxyurea therapy starting at about 20mg/kg/day. Changes in the frequency and severity of each test (neurological and cognitive tests and cerebral blood flow velocity) will be compared with their baseline tests (prior to hydroxyurea) by repeating these tests at 18 and 36 months. In a randomly selected subset of 90 participants, an evaluation of the impact of hydroxyurea on structural brain vascular injury using magnetic resonance brain imaging (MRI) and magnetic vessel imaging ,also called angiography (MRA) at baseline and at 36 months. Lastly, an assessment of changes to biomarkers of anemia, inflammation and malnutrition from before and during hydroxyurea therapy and determine their relationship to the outcomes. The proposed intervention with hydroxyurea is the first Africa-based trial to broadly prevent or ameliorate manifestations of SCV.


Description:

Annually, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) worldwide. Affected children often suffer repeated acute illnesses and chronic ill health from vascular occlusive phenomenon. In particular, they are at a high risk of stroke due to the development of sickle cell cerebral vascular (SCV) injury. SCV can also cause neurocognitive impairment. Stroke risk may be predicted by abnormal cerebral arterial flow detected by transcutaneous Doppler ultrasound (TCD). The specific aims are: Aim 1: Determine the impact of hydroxyurea therapy on the frequency and severity of SCV in a cohort of children treated for three years, as measured by 3 distinct outcomes: abnormal TCD, neurocognitive impairment and primary stroke, compared with baseline. Aim 2: Evaluate the impact of hydroxyurea on structural SCV using MRI and MRA in a randomly selected subset of this cohort. Aim 3: Assess changes to anemia, malnutrition status, C-reactive protein and other inflammatory markers during hydroxyurea therapy, over time, compared with baseline levels. Design: This will an open label, single arm trial of hydroxyurea to test the three year impact of hydroxyurea treatment in children with SCA on each of three clinically important outcomes: abnormal cerebral arterial flow, neurocognitive impairment and primary stroke. In aim 1, there will be enrollment of a new longitudinal cohort of 270 children ages 3-9 years selected randomly from among eligible patients attending Mulago hospital SCA clinic (MHSCC) roster, without evidence of prior stroke by examination. The hypothesis is that hydroxyurea therapy will prevent, stabilize or improve Sickle Cell Vasculopathy(SCV) and its effects. Eligible subjects will be evaluated by TCD, stroke-focused neurological examination and neurocognitive testing at baseline. Following initial assessments, study subjects will begin standardized hydroxyurea therapy. Overtime, changes in the frequency and severity of each distinct measure of SCV with baseline by repeating these three tests at 18 and 36 months and against the age specific prevalence of SCV in children who did not receive any intervention in the earlier BRAIN SAFE I observational study (our historical cohort). In Aim 2, a subset of the study subjects, a randomly selected subset of 90 subjects, will undergo brain imaging at baseline and at 36 months to assess structural findings over time. The hypothesis is that prospective brain imaging by MRI and MRA provides critical structural definitions [1,2] of SCV changes or stabilization over three years compared to baseline, while on hydroxyurea. Results of brain imaging and biomarkers will be correlated with these outcomes over time. In aim 3, there will be prospective examination for risk factors of SCV overtime. Biomarkers for risk of SCV may include severe anemia, the inflammatory marker C- reactive protein (CRP) and malnutrition status. The hypothesis is that a higher burden of anemia, inflammation and malnutrition predispose African children with SCA to greater burden of SCV than in the West. Changes in the values of these biomarkers will be assessed over time while on hydroxyurea Site: Participants will be recruited from Mulago hospital Sickle Cell Anemia Clinic in Kampala, Uganda. Follow up: Participants will be on study medication and follow-up for 36 months. Data Analysis: The investigators will estimate the effects of hydroxyurea for each distinct endpoint, (stroke, abnormal TCD or impaired cognition) by comparing against the age specific prevalence in children who did not receive any intervention in the earlier BRAIN SAFE I study. To assess the risk of stabilization or reduction in SCV, time to event analyses using Cox proportional hazards modelling will be used after Kaplan Meier curves are generated. Multilevel regression models will be used to asses within and between subject changes over time for continuous measures of TCD velocity and cognitive z-scores.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 270
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 9 Years
Eligibility Inclusion Criteria: 1. Documented laboratory diagnosis of HbSS or HbS-B 0 thalassemia (both types are treated equally in SCA studies) 2. Ages 3 through 9 years (inclusive) at enrolment 3. To ensure clinic follow-up, child has attended Mulago Hospital Sickle Cell Anaemia (SCA)clinic 2 times in the prior 4 years, or at least once in the past 2 years if younger than < 4 years 4. No history of hydroxyurea use for longer than 6 months 5. Parent/legal guardian has provided a written consent (and if child is =8 years of age, has provided assent) Exclusion Criteria: 1. History of neurological abnormality known before age 4 months (to avoid those with non SCA brain injury) 2. Child is currently enrolled in another clinical intervention trial 3. Prior stroke as detected by standard Pediatric NIH Stroke Scale (PedNIHSS) examination Temporary exclusion criteria 4. Pre-existing hematological toxicity 1. Hemoglobin <4.0 gm/dL 2. Hemoglobin <6.0 gm/dL with Absolute Reticulocyte Count <100 x 10 9/L 3. Absolute Reticulocyte Count <80 x 109/L with Hemoglobin <7.0 gm/dL 4. Platelets <80 x 109/L 5. Absolute Neutrophil Count <1.0 x 109/L 5. Found to be with acute illness at enrolment with fever in last 1 week, respiratory infection, etc. 6. History of a sickle crisis within the prior 2 weeks, or blood transfusion within the past 90 days Participants with temporary exclusion can be enrolled later when stable or the excluding criteria has resolved

Study Design


Intervention

Drug:
Hydroxyurea
The study intervention will be daily oral Hydroxyurea given in single doses starting at approximately 20mg/kg/day and escalated to a maximum 30mg/kg/day depending on clinical need and according to standard guidelines.

Locations

Country Name City State
Uganda Global Health Uganda Kampala

Sponsors (7)

Lead Sponsor Collaborator
Global Health Uganda LTD Columbia University, Emory University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Makerere University, Mulago Hospital, Uganda, University of Pittsburgh

Country where clinical trial is conducted

Uganda, 

References & Publications (1)

Galadanci NA, Umar Abdullahi S, Vance LD, Musa Tabari A, Ali S, Belonwu R, Salihu A, Amal Galadanci A, Wudil Jibir B, Bello-Manga H, Neville K, Kirkham FJ, Shyr Y, Phillips S, Covert BV, Kassim AA, Jordan LC, Aliyu MH, DeBaun MR. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017 Aug;92(8):780-788. doi: 10.1002/ajh.24770. Epub 2017 Jun 15. Erratum In: Am J Hematol. 2018 Mar;93(3):E83. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The frequency, age specific prevalence and severity of Sickle Cell Vasculopathy manifested by New stroke as assessed by the Pediatric NIH Stroke Scale (PedNIHSS) over the 3-year study while on hydroxyurea treatment, compared to baseline assessments. Baseline assessment will be completed for all study participants and over the 3-year study, scheduled outcome assessments will be performed at study months 18 and 36.
These assessments will aim to document New (incident) stroke as assessed by the PedNIHSS
3 years
Primary The frequency, age specific prevalence and severity of Sickle Cell Vasculopathy manifested by a change in transcranial doppler (TCD) velocity by 15cm/sec or more over the 3-year study while on hydroxyurea treatment, compared to baseline assessment. Baseline assessment will be completed for all study participants and over the 3-year study, scheduled outcome assessments will be performed at study months 18 and 36.These assessments will aim to document a change in TCD velocity by 15cm/sec or more. 3 years
Primary The frequency, age specific prevalence and severity of SCV manifested by New or worsening cognitive impairment, both quantitative and categorical over the 3-year study while on hydroxyurea treatment, compared to baseline assessments. Baseline assessment will be completed for all study participants and over the 3-year study, scheduled outcome assessments will be performed at study months 18 and 36.These assessments will aim to document new or worsening cognitive impairment - both quantitative and categorical (by standardized criteria =-2 z-score) compared to established criteria 3 years
Secondary Stabilized or worsened structural changes on brain Magnetic Resonance Imaging(MRI) over the 3 years compared to baseline Brain magnetic resonance will be performed on a subset of subjects at baseline and study month 36 only. Stabilized or worsened structural changes on brain Magnetic Resonance Imaging(MRI) over the 3 years compared to baseline will be assessed. 3 years
Secondary Stabilized or worsened structural changes on brain Magnetic Resonance Angiography(MRA) over the 3 years compared to baseline Brain magnetic resonance angiography will be performed on a subset of subjects, at baseline and study month 36 only. Stabilized or worsened structural changes on brain Magnetic Resonance Angiography over the 3 years compared to baseline will be assessed. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06387758 - Low Systemic/High Local Exercise Load in Peds SCD N/A
Completed NCT04579926 - PINPOINT: Gaming Technology for SCD Pain N/A
Completed NCT03632876 - Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD N/A
Recruiting NCT05285917 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa Phase 3
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT03176849 - A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Phase 4
Recruiting NCT05018728 - The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia Phase 2
Recruiting NCT04191213 - Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients Phase 2/Phase 3
Completed NCT04844099 - Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia Phase 3
Enrolling by invitation NCT03948867 - Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE) Phase 2
Completed NCT04800809 - The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria